Business Blockbuster - Helpng business to be more visible on Google
The Times Australia

Hardman & Co Life Sciences Research: Long-term pharmaceutical industry cost and EBIT analysis

LONDON, UK - EQS Newswire - 10 June 2022 - Financial information from over 100 multinational drug companies, involving over 70,000 data points, have been accumulated over the past 35 years to create a pharmaceutical database.

All our data (sales, COGS, SG&A, R&D and other income) have been derived from annual reports, regulatory filings and company presentations, and then analysed, wherever possible, in a like-for-like manner, irrespective of how each company presents the data. This is a key differentiator to competitive products and is important because all company management teams report "adjusted", "core", or "non-GAAP" earnings to show themselves in the best possible light. However, different inclusion/exclusion criteria in the generation of these adjustments lead to distortions and variability.

Although some of the companies are multi-divisional, another key differentiator is the extraction and analysis of data for the pharmaceutical segment only. This product is unique because it analyses the individual cost components of each company over time and generates pharma industry weighted averages, allowing peer and industry comparisons to be made. It also generates individual company and industry-wide underlying operating profit (EBIT), both pre-R&D and post R&D.

Historically, data from over 100 companies has been accumulated, but industry consolidation means that just 40 are included currently, which command an estimated 76% of the global drug industry. The main exceptions are the Chinese companies where insufficient data are available on a consistent basis.

Current companies included in dataset:

pharma.png

Click here to find out more:
https://hardmanandco.com/2021-pharma-statistics-long-term-cost-underlying-ebit-analysis/

Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259. Attention is drawn to the important disclaimers at the end of the report.

Times Magazine

What is a passkey — and should you use one instead of a password?

Websites increasingly invite users to create a passkey. The unfamiliar name describes a simpler wa...

A quality cut to bills for Beaufort butcher

Victorians are increasingly turning to Easy Electric SEC to better understand their home energy op...

Mentoring - Raising a child is more than providing for one

Food, shelter, safety and schooling are essential. But the guidance children receive about how to ...

Technology

What is a passkey — and should you …

Websites increasingly invite users to create a passkey. The unfamiliar name describes a simpler wa...

Local News

From paediatric nurse to trans-Tasm…

The time-honoured tradition of showing up with a home-cooked meal is getting a modern makeover, wi...

Culture

Head Injuries in Children and Adults: When Im…

Head injury scans are among the most time-critical imaging tests, and also among the most misunderst...

Travel

Jet Skis to Launch Surfers Skyward at Scarbor…

Twenty of WA's most exciting aerial surfers will be towed into waves at speed for Red Bull Aeriali...

The Times Features

Head Injuries in Children and Adults: When Imaging Is C…

Head injury scans are among the most time-critical imaging tests, and also among the most misunderst...

Kinder Unwraps Christmas 2026 with Personalised Santa S…

This Christmas, Kinder is making the festive season even more magical with a range of delicious ch...

Jet Skis to Launch Surfers Skyward at Scarborough Beach

Twenty of WA's most exciting aerial surfers will be towed into waves at speed for Red Bull Aeriali...